Pure Global
NCT06366490

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer

Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients With Recurrent Epithelial Ovarian Cancer
PhotonPharma, Inc.·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
Innocell Autologous Cellular Immunotherapy
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
PhotonPharma, Inc.
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2024
End date
Mar 01, 2025
Enrollment
8 participants
Primary outcome

Saferty and Immunogenicity of Innocell in Ovarian Cancer Patients,Safety of Innocell in Ovarian Cancer Patients,Immunogenicity of Innocell in Ovarian Cancer Patients,Immunogemicity in Ovarian Cancer Patients,Immunogenicity of Innocell Vaccine in Ovarian Cancer Patients

Summary

Safety and Immunogenicity of InnocellTM Autologous Cellular Immunotherapy Administered in
 Patients with Recurrent Epithelial Ovarian Cancer

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06366490
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06366490 through Pure Global AI's free database. This Phase 1 trial is sponsored by PhotonPharma, Inc. and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.